Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.
作者信息
Berger Joseph R, Hartung Hans-Peter
机构信息
Department of Neurology, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, United States.
Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
出版信息
Front Neurol. 2023 Mar 16;14:1146027. doi: 10.3389/fneur.2023.1146027. eCollection 2023.
Abstract
摘要
相似文献
1
Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.
Front Neurol. 2023 Mar 16;14:1146027. doi: 10.3389/fneur.2023.1146027. eCollection 2023.
2
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.
Front Neurol. 2022 Dec 14;13:1016377. doi: 10.3389/fneur.2022.1016377. eCollection 2022.
3
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Lancet Neurol. 2017 Nov;16(11):925-933. doi: 10.1016/S1474-4422(17)30282-X. Epub 2017 Sep 29.
4
Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy.
Front Neurol. 2020 Mar 17;11:186. doi: 10.3389/fneur.2020.00186. eCollection 2020.
5
Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.
J Neurovirol. 2017 Oct;23(5):742-749. doi: 10.1007/s13365-017-0561-9. Epub 2017 Aug 8.
6
Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Mult Scler. 2016 Aug;22(9):1174-83. doi: 10.1177/1352458515615225. Epub 2015 Nov 12.
7
Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance.
J Neurol. 2020 Sep;267(9):2599-2602. doi: 10.1007/s00415-020-09880-7. Epub 2020 May 8.
8
Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.
9
Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review.
Cureus. 2021 Apr 30;13(4):e14764. doi: 10.7759/cureus.14764.
10
[A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):98-106. doi: 10.17116/jnevro20191192298.
引用本文的文献
1
Genetics of progressive multifocal leukoencephalopathy: update on case reports with an inborn error of immunity and risk variants found in drug-linked cases.
Front Neurol. 2025 Jul 15;16:1629581. doi: 10.3389/fneur.2025.1629581. eCollection 2025.
2
Highly restrictive and directional penetration of the blood cerebral spinal fluid barrier by JCPyV.
PLoS Pathog. 2024 Jul 22;20(7):e1012335. doi: 10.1371/journal.ppat.1012335. eCollection 2024 Jul.
3
Progressive multifocal leukoencephalopathy and spectrum of predisposing conditions: a 20-year retrospective cohort study in a tertiary center in São Paulo, Brazil.
Neurol Sci. 2025 Jan;46(1):365-379. doi: 10.1007/s10072-024-07669-4. Epub 2024 Jul 15.
4
Revisiting JC virus and progressive multifocal leukoencephalopathy.
J Neurovirol. 2023 Oct;29(5):524-537. doi: 10.1007/s13365-023-01164-w. Epub 2023 Sep 2.
5
An Elusive Target: Inhibitors of JC Polyomavirus Infection and Their Development as Therapeutics for the Treatment of Progressive Multifocal Leukoencephalopathy.
Int J Mol Sci. 2023 May 11;24(10):8580. doi: 10.3390/ijms24108580.
本文引用的文献
1
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies.
Front Neurol. 2022 Dec 14;13:1016377. doi: 10.3389/fneur.2022.1016377. eCollection 2022.
2
Evolution of immune genes is associated with the Black Death.
Nature. 2022 Nov;611(7935):312-319. doi: 10.1038/s41586-022-05349-x. Epub 2022 Oct 19.
3
Genetics Insight for COVID-19 Susceptibility and Severity: A Review.
Front Immunol. 2021 Apr 1;12:622176. doi: 10.3389/fimmu.2021.622176. eCollection 2021.
4
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.
Nat Rev Neurol. 2021 Jan;17(1):37-51. doi: 10.1038/s41582-020-00427-y. Epub 2020 Nov 20.
5
Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy.
Front Neurol. 2020 Mar 17;11:186. doi: 10.3389/fneur.2020.00186. eCollection 2020.
6
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
Lancet Neurol. 2018 May;17(5):467-480. doi: 10.1016/S1474-4422(18)30040-1.
7
Progressive multifocal leukoencephalopathy.
Handb Clin Neurol. 2014;123:357-76. doi: 10.1016/B978-0-444-53488-0.00017-1.
8
Natural selection and infectious disease in human populations.
Nat Rev Genet. 2014 Jun;15(6):379-93. doi: 10.1038/nrg3734. Epub 2014 Apr 29.
9
Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease.
Clin Exp Immunol. 2009 Sep;157(3):395-9. doi: 10.1111/j.1365-2249.2009.03975.x.
10
MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement.
Mol Immunol. 2009 Sep;46(14):2737-44. doi: 10.1016/j.molimm.2009.05.005. Epub 2009 Jun 7.
Zotero 插件